George W. Koszalka

2.9k total citations · 1 hit paper
56 papers, 2.4k citations indexed

About

George W. Koszalka is a scholar working on Molecular Biology, Epidemiology and Infectious Diseases. According to data from OpenAlex, George W. Koszalka has authored 56 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 24 papers in Epidemiology and 11 papers in Infectious Diseases. Recurrent topics in George W. Koszalka's work include Biochemical and Molecular Research (20 papers), Cytomegalovirus and herpesvirus research (13 papers) and Herpesvirus Infections and Treatments (11 papers). George W. Koszalka is often cited by papers focused on Biochemical and Molecular Research (20 papers), Cytomegalovirus and herpesvirus research (13 papers) and Herpesvirus Infections and Treatments (11 papers). George W. Koszalka collaborates with scholars based in United States, United Kingdom and China. George W. Koszalka's co-authors include Thomas A. Krenitsky, Joel V. Tuttle, John C. Drach, Leroy B. Townsend, Janet L. Rideout, Gertrude B. Elion, S.E. Ealick, L M Beacham, Karen K. Biron and Steven A. Short and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Biochemistry.

In The Last Decade

George W. Koszalka

56 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity.

1976 192 citations Thomas A. Krenitsky, Joel V. Tuttle et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George W. Koszalka United States	24	1.2k	855	593	508	356	56	2.4k
Mahmoud H. el Kouni United States	28	1.4k 1.1×	648 0.8×	388 0.7×	409 0.8×	616 1.7×	88	2.5k
Harry Ford United States	24	1.2k 0.9×	392 0.5×	681 1.1×	464 0.9×	233 0.7×	58	1.8k
Chris Meier Germany	32	2.1k 1.7×	840 1.0×	1.6k 2.8×	1.5k 2.9×	253 0.7×	224	3.8k
Howard J. Schaeffer United States	20	1.0k 0.8×	1.2k 1.4×	511 0.9×	591 1.2×	320 0.9×	66	2.6k
Ginger E. Dutschman United States	32	1.4k 1.1×	1.0k 1.2×	1.3k 2.2×	555 1.1×	467 1.3×	88	3.1k
Thomas P. Zimmerman United States	26	1.1k 0.9×	518 0.6×	458 0.8×	135 0.3×	277 0.8×	68	2.1k
Jean‐Louis Imbach France	33	3.4k 2.7×	758 0.9×	1.6k 2.6×	1.6k 3.1×	211 0.6×	254	4.8k
David N. Standring United States	30	1.4k 1.1×	1.8k 2.1×	834 1.4×	450 0.9×	163 0.5×	59	3.7k
R W Brockman United States	32	1.7k 1.4×	350 0.4×	447 0.8×	376 0.7×	453 1.3×	70	2.7k
Sue C. Shaddix United States	18	686 0.6×	184 0.2×	444 0.7×	274 0.5×	276 0.8×	35	1.3k

Countries citing papers authored by George W. Koszalka

Since Specialization

Citations

This map shows the geographic impact of George W. Koszalka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George W. Koszalka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George W. Koszalka more than expected).

Fields of papers citing papers by George W. Koszalka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George W. Koszalka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George W. Koszalka. The network helps show where George W. Koszalka may publish in the future.

Co-authorship network of co-authors of George W. Koszalka

This figure shows the co-authorship network connecting the top 25 collaborators of George W. Koszalka. A scholar is included among the top collaborators of George W. Koszalka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George W. Koszalka. George W. Koszalka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Haichen, Raymond Dingledine, Scott J. Myers, et al.. (2024). Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage. Journal of Pharmacology and Experimental Therapeutics. 392(1). 100046–100046. 4 indexed citations

Zaczek, Robert, Stephen F. Traynelis, Raymond Dingledine, George W. Koszalka, & Daniel T. Laskowitz. (2023). Phase 1 Clinical Results for NP10679, a pH‐sensitive GluN2B‐selective N‐methyl‐d‐aspartate Receptor Inhibitor. Clinical Pharmacology in Drug Development. 12(7). 706–717. 7 indexed citations

Myers, Scott J., Lawrence J. Wilson, Yesim A. Tahirovic, et al.. (2021). A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B–Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use. Journal of Pharmacology and Experimental Therapeutics. 379(1). 41–52. 10 indexed citations

Bading, James R., Antranik Shahinian, George W. Koszalka, et al.. (2004). Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-β-d-arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nuclear Medicine and Biology. 31(4). 407–418. 30 indexed citations

Chan, Joseph H., George A. Freeman, Jeffrey H. Tidwell, et al.. (2004). Novel Benzophenones as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1. Journal of Medicinal Chemistry. 47(5). 1175–1182. 52 indexed citations

Stafford, Jeffrey A., Gregory J. Pacofsky, Richard F. Cox, et al.. (2002). Identification and Structure–Activity Studies of Novel Ultrashort-Acting Benzodiazepine Receptor Agonists. Bioorganic & Medicinal Chemistry Letters. 12(21). 3215–3218. 24 indexed citations

Biron, Karen K., Richard J. Harvey, Steven S. Good, et al.. (2002). Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of Action. Antimicrobial Agents and Chemotherapy. 46(8). 2365–2372. 295 indexed citations

Zou, Ruiming, Etsuko Kawashima, George A. Freeman, et al.. (2000). Design, Synthesis, and Antiviral Evaluation of 2-Deoxy-D-Ribosides of Substituted Benzimidazoles as Potential Agents for Human Cytomegalovirus Infections. Nucleosides Nucleotides & Nucleic Acids. 19(1-2). 125–153. 14 indexed citations

Chulay, Jeffrey D., Karen K. Biron, Mark Underwood, et al.. (1999). Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Disease. Advances in experimental medicine and biology. 458. 129–134. 39 indexed citations

10.

Townsend, Leroy B., Kristjan S. Gudmundsson, Susan M. Daluge, et al.. (1999). Studies Designed to Increase the Stability and Antiviral Activity (HCMV) of the Active Benzimidazole Nucleoside, TCRB. Nucleosides and Nucleotides. 18(4-5). 509–519. 27 indexed citations

11.

Mao, Chen, William J. Cook, Min Zhou, et al.. (1997). The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 5(10). 1373–1383. 114 indexed citations

12.

Chamberlain, Stanley D., Karen K. Biron, Ronna E. Dornsife, et al.. (1994). An Enantiospecific Synthesis of the Human Cytomegalovirus Antiviral Agent [(R)-3-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-4- hydroxybutyl]phosphonic Acid. Journal of Medicinal Chemistry. 37(9). 1371–1377. 21 indexed citations

13.

Perlman, Michael E., Donald G. Davis, George W. Koszalka, Joel V. Tuttle, & Robert E. London. (1994). Studies of Inhibitor Binding to Escherichia coli Purine Nucleoside Phosphorylase Using the Transferred Nuclear Overhauser Effect and Rotating-Frame Nuclear Overhauser Enhancement. Biochemistry. 33(24). 7547–7559. 19 indexed citations

14.

Koszalka, George W., et al.. (1994). Synthesis and Biological Evaluation of Pyrimidine and Purine α-L-2′,3′-Dideoxy Nucleosides. Nucleosides and Nucleotides. 13(8). 1679–1693. 14 indexed citations

15.

Soike, Kenneth F., C U Lambe, Donald J. Nelson, et al.. (1993). 6-Dimethylamino-9-(β-d-arabinofuranosyl)-9H-purine: Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys. Antiviral Research. 20(1). 13–20. 1 indexed citations

16.

Fyfe, James A., Shahnaz Rahim, Susan M. Daluge, et al.. (1993). Varicella-Zoster virus thymidine kinase. Biochemical Pharmacology. 46(12). 2209–2218. 12 indexed citations

17.

Domin, Barbara A., et al.. (1992). Membrane permeation characteristics of 5'-modified thymidine analogs.. Molecular Pharmacology. 41(5). 950–956. 10 indexed citations

18.

Walter, Mark R., W.J. Cook, L. Brent Cole, et al.. (1990). THREE-DIMENSIONAL STRUCTURE OF THYMIDINE PHOSPHORYLASE FROM ESCHERICHIA COLI AT 2.8 ANGSTROMS RESOLUTION. PubMed. 265(23). 14016–22. 90 indexed citations

19.

Krenitsky, Thomas A., Janet L. Rideout, Esther Y. Chao, et al.. (1986). Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents. Journal of Medicinal Chemistry. 29(1). 138–143. 61 indexed citations

20.

Krenitsky, Thomas A., George W. Koszalka, Joel V. Tuttle, Janet L. Rideout, & Gertrude B. Elion. (1981). An enzymic synthesis of purine d-Arabinonucleosides. Carbohydrate Research. 97(1). 139–146. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact